Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

438
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
438
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

19
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same author

Revascularization with drug-coated balloons alone in complex coronary artery disease: a systematic review.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Paclitaxel-coated balloon treatment is associated with sympathetic coronary denervation in a porcine model.

Scientific reports·2026
Same author

Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry.

Journal of clinical medicine·2026
Same author

Towards Neoatherosclerosis: A Porcine Model for Enhanced Device Testing.

Journal of cardiovascular translational research·2026
Same author

The European bifurcation club randomized trial of stepwise provisional stenting vs drug-coated balloon therapy for nonleft main true coronary bifurcations: The EBC DCB trial.

American heart journal·2026

Related Experiment Video

Updated: Aug 23, 2025

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K

Drug-Coated Balloons: Drugs Beyond Paclitaxel?

Tobias Haase1,2, Ulrich Speck1, Stephanie Bienek2

  • 1Experimental Radiology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.

Frontiers in Bioscience (Landmark Edition)
|November 7, 2022
PubMed
Summary
This summary is machine-generated.

Paclitaxel remains the only effective drug for drug-coated balloons (DCBs) inhibiting restenosis. Preclinical studies found no alternative drug candidates, including limus drugs, that matched paclitaxel

Keywords:
coronary heart diseasedrug coated balloonsendovascular therapiesin-stent stenosisneointima formationpaclitaxel

More Related Videos

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

23.1K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K

Related Experiment Videos

Last Updated: Aug 23, 2025

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.0K
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
08:41

Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice

Published on: October 27, 2014

23.1K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

9.1K

Area of Science:

  • Cardiovascular Research
  • Biomedical Engineering
  • Pharmacology

Background:

  • Paclitaxel is the only clinically proven drug for inhibiting restenosis via drug-coated balloons (DCBs).
  • Limus drugs are being explored as potential alternatives to paclitaxel for DCBs.
  • This study investigated novel drug candidates for balloon coating beyond paclitaxel.

Purpose of the Study:

  • To evaluate alternative drug candidates for DCBs in preclinical models.
  • To assess the efficacy of various drugs in preventing neointimal proliferation after stenting.
  • To compare the performance of novel drug coatings against paclitaxel and uncoated balloons.

Main Methods:

  • Drugs were tested for solubility, balloon coating feasibility, and vascular drug transfer.
  • The porcine coronary in-stent restenosis model was used to assess neointimal proliferation inhibition.
  • Drug-eluting balloons (DEBs) were employed for intravascular drug delivery during stent implantation.

Main Results:

  • Drug transfer to the vessel wall ranged from 5% to 29% of initial doses.
  • None of the tested drugs (arsenic trioxide, betamethasone, bortezomib, green tea extract, fantolon, methotrexate, thalidomide) significantly reduced late lumen loss (LLL) compared to uncoated balloons.
  • Paclitaxel coatings reliably reduced in-stent stenosis, achieving an LLL of 0.36 ± 0.25 mm.

Conclusions:

  • Despite known antiproliferative or anti-inflammatory effects, tested drug coatings did not significantly reduce LLL.
  • None of the investigated drug candidates demonstrated efficacy comparable to paclitaxel for DCBs.
  • The findings suggest that current paclitaxel-based coatings remain the standard for inhibiting restenosis via DCBs.